- In March 2012, the Company announced the results from two phase 1 clinical studies requested by the U.S. Food and Drug Administration (FDA) in its Complete Response Letter for APF530. The results of these studies will be included in the resubmission of the New Drug Application (NDA).
- The Company completed a thorough QT study for APF530 showing that granisetron, the active drug used in APF530, does not have an effect on cardiac repolarization as measured by prolongation of the QT interval.
- A separate metabolism study was completed that showed how the human body processes APF530 and corroborated preclinical animal data.
- The Company is awaiting the review of its non-clinical human factors validation study protocol by the FDA and anticipates performing this study in the second quarter of 2012. The validation study protocol is based on previously completed formative studies, and the results will be included in the NDA resubmission.
- On March 26, 2012, the Company announced the appointment of Thomas Ottoboni, Ph.D. as Vice President of Pharmaceutical Development.
- On May 8, 2012, the Company received $3 million of cash through the issuance of convertible notes pursuant to a second closing of the private placement financing for up to $4.5 million announced in April 2011.
Cash and cash equivalents as of March 31, 2012 were $13.4 million, compared to $18.0 million at December 31, 2011. The $3.0 million of cash received through the issuance of convertible notes by the Company in May 2012 results in cash and cash equivalents of $16.4 million as of March 31, 2012 on a pro forma basis. Net cash used in operating activities was $4.1 million for the quarter ended March 31, 2012. The Company believes that its current cash resources are sufficient to fund its operations into 2013.About APF530 A.P. Pharma's lead product, APF530, is in development for the prevention of both acute-onset and delayed-onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company’s proprietary Biochronomer™ drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of acute-onset CINV, but not delayed-onset CINV. Granisetron was selected because it is widely prescribed by physicians based on a well-established record of safety and efficacy. About A.P. Pharma A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company’s primary focus is on its lead product, APF530, for the prevention of CINV. A.P. Pharma received a Complete Response Letter on the APF530 NDA and is targeting the resubmission of the NDA in mid-2012. The Company has additional research and development programs that utilize its bioerodible, injectable and implantable delivery systems. For further information, please visit the Company's web site at www.appharma.com. (financial tables follow)
|A.P. Pharma, Inc.|
|Condensed Statements of Operations|
|(in thousands, except per share amounts)|
|Three Months EndedMarch 31,|
|Research and development||3,329||1,141|
|General and administrative||1,440||569|
|Total operating expenses||4,769||1,710|
|Interest expense, net||(61||)||(1||)|
|Loss from continuing operations||(4,830||)||(1,316||)|
|Loss from discontinued operations||(91||)||(103||)|
|Basic and diluted net loss per share:|
|Loss from continuing operations||$||(0.02||)||$||(0.03||)|
|Shares used to compute basic and diluted net loss per share||200,046||39,869|
|A.P. Pharma, Inc.|
|Condensed Balance Sheets|
|March 31, 2012||December 31, 2011|
|Cash and cash equivalents||$||13,444||$||17,974|
|Prepaid expenses and other current assets||306||266|
|Total current assets||13,750||18,240|
|Property and equipment, net||1,114||1,075|
|Other long-term assets||130||130|
|Liabilities and Stockholders' Equity|
|Accrued disposition costs||1,173||1,082|
|Convertible notes payable to related parties, net of discount||143||103|
|Total current liabilities||3,361||3,693|
|Additional paid-in capital||174,791||173,989|
|Total stockholders' equity||11,633||15,752|
|Total liabilities and stockholders' equity||$||14,994||$||19,445|